Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
'State Govt Needs To Take A Stand': Sena UBT's Ambadas Danve Urges Action Against Sena MLA Mahendra Dalvi Over Viral 'Cash Video'
Ro-Ko Supremacy! Rohit Sharma & Virat Kohli Secure Dominant 1-2 Position In ICC Men's ODI Batting Rankings
Maharashtra Assembly Speaker Narwekar Slams EV Toll Collection On Mumbai-Pune Expressways, Urges Government To Implement Waiver System Within Eight Days
Redmi 15C Review: A No-Nonsense Budget Phone That Plays It Safe?
